HomeLatest FeedsTechnology NewsNext year, oral insulin - PCW - will be tested on humans

Next year, oral insulin – PCW – will be tested on humans



Compared to the injection, the side effects are almost insignificant.

Diabetes is one of the most common chronic diseases in the world. Although there are no exact data due to the high rate of latency, the number of people with type 2 diabetes, which is the most common form of the disease, can be estimated at hundreds of millions globally.

If the blood sugar level measured on an empty stomach exceeds the value of 13.9 mmol/l, the patient must regularly normalize the blood sugar level with insulin injections for his own well-understood benefit. In the absence of this, the patient may lose weight, feel bad, and in severe cases may even die.

In addition to the discomfort, those whose illness condemns them to regular use of medicinal products have to deal with a series of difficulties. Insulin ampoules must be stored refrigerated, and recently there was a shortage in our country due to a different application.

The project of the Norwegian UiT Norway’s Arctic University and the Australian University of Sydney can now provide a solution to these problems, in the framework of which patients in need of insulin can replace the cumbersome injection with a capsule. The active ingredient in the “intelligent” capsule only takes effect when necessary, that is, when the blood sugar level rises.

The capsules contain quantum dots made of silver sulfide combined with insulin. These nano-sized particles deliver the active ingredient in a targeted manner where it is needed, while a polymer coating protects them from the corrosive effects of stomach acid. This also prevents the medicine from taking effect prematurely, since the components of the coating that react to the difference in pH level can only be broken down by those enzymes that are activated in the event of high blood sugar levels.

Several pharmaceutical companies have similar research, but none of them is as advanced as the Norwegian-Australian joint development. The results of experiments on mice and monkeys are encouraging, so soon, during the course of next year, experiments on humans can begin. In the first instance, the answer is sought as to whether hyperglycemia can be prevented by using the preparation, and then the physiological effects of the medicine are examined in comparison with the injection.

If everything goes according to plan, after the human tests started next year, the innovative oral medicine could be on the market within 2-3 years as an alternative to injections.

Mr.Mario
Mr.Mario
I am a tech enthusiast, cinema lover, and news follower. and i loved to be stay updated with the latest tech trends and developments. With a passion for cyber security, I continuously seeks new knowledge and enjoys learning new things.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Must Read